Want to see GNLX full AI Analyst Report?
GNLX Stock Chart & Stats
$2.72
$0.03(1.21%)
At close: 4:00 PM EDT
$2.72
$0.03(1.21%)
Day’s Range― - ―
52-Week Range$2.29 - $8.54
Previous CloseN/A
Volume44.18K
Average Volume (3M)156.94K
Market Cap
$123.07M
Enterprise Value$119.08
Total Cash (Recent Filing)$18.67M
Total Debt (Recent Filing)$2.42M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Nov 18, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.89
Shares Outstanding45,245,335
10 Day Avg. Volume178,540
30 Day Avg. Volume156,945
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)14.04
Price to Sales (P/S)20261.21
P/FCF Ratio-6.15
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$19.67Price Target Upside623.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.82
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-Stage Clinical ProgramA Phase 3 registrational trial provides a potentially important path toward demonstrating olvi-vec efficacy in ovarian cancer. Positive topline results could materially advance the asset toward regulatory review and commercial development.
Clinical Mechanism SupportTranslational evidence supporting the proposed mechanism strengthens the scientific rationale for combining olvi-vec with chemotherapy. This may improve development credibility and support expansion across solid-tumor programs if clinical findings are consistent.
Modest LeverageModest debt relative to equity limits interest and repayment pressure compared with more highly levered biotechs. This gives Genelux somewhat greater financial flexibility to prioritize clinical development, although it does not remove funding risk.
Bears Say
Minimal Revenue And Deep LossesGenelux has no meaningful recurring revenue base and remains deeply unprofitable. The gap between minimal revenue and substantial operating costs indicates that the business currently depends on successful clinical advancement rather than operating performance.
Heavy Cash BurnLarge cash outflows show that clinical operations are not self-funding and that losses are translating into real liquidity consumption. Continued development will likely require additional capital before any product revenue can support the business.
Funding And Dilution RiskThe stated runway is limited relative to the company’s ongoing burn and development obligations. If trials continue without commercial revenue, future financing may be necessary, creating dilution or recapitalization risk for existing shareholders.
Genelux Corp. News
GNLX FAQ
What was Genelux Corp.’s price range in the past 12 months?
Genelux Corp. lowest stock price was $2.29 and its highest was $8.54 in the past 12 months.
What is Genelux Corp.’s market cap?
Genelux Corp.’s market cap is $123.07M.
When is Genelux Corp.’s upcoming earnings report date?
Genelux Corp.’s upcoming earnings report date is Nov 18, 2026 which is in 83 days.
How were Genelux Corp.’s earnings last quarter?
Genelux Corp. released its earnings results on Aug 13, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.197 by -$0.013.
Is Genelux Corp. overvalued?
According to Wall Street analysts Genelux Corp.’s price is currently Undervalued.
Does Genelux Corp. pay dividends?
Genelux Corp. does not currently pay dividends.
What is Genelux Corp.’s EPS estimate?
Genelux Corp.’s EPS estimate is -0.2.
How many shares outstanding does Genelux Corp. have?
Genelux Corp. has 45,245,335 shares outstanding.
What happened to Genelux Corp.’s price movement after its last earnings report?
Genelux Corp. reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.197. Following the earnings report the stock price went up 4.183%.
Which hedge fund is a major shareholder of Genelux Corp.?
Currently, no hedge funds are holding shares in GNLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genelux Corp. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.67 (623.04% Upside)
$19.67 (623.04% Upside)
Hedge Fund Trend
Decreased
By 631.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $48.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 12.5%
Last 30 Days ▼ 12.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
136.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.74%
Trailing 12-Months
Company Description
Genelux Corp.
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
GNLX Stock 12 Month Forecast
Average Price Target
$19.67
▲(623.04% Upside)
Technical Analysis
Coherus Biosciences
―
Fate Therapeutics
―
Tonix Pharma
―
Corbus Pharmaceuticals
―
Forte Biosciences
―
Ownership Overview
7.14% Insiders
4.62% Mutual Funds
10.87% Other Institutional Investors
73.38% Public Companies and
Individual Investors